CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation
NYSE:CRL • US1598641074
Current stock price
155.46 USD
+2.8 (+1.83%)
At close:
155.46 USD
0 (0%)
After Hours:
This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CRL Profitability Analysis
1.1 Basic Checks
- CRL had positive earnings in the past year.
- In the past year CRL had a positive cash flow from operations.
- CRL had positive earnings in 4 of the past 5 years.
- CRL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- CRL's Return On Assets of -2.02% is in line compared to the rest of the industry. CRL outperforms 57.89% of its industry peers.
- CRL's Return On Equity of -4.56% is in line compared to the rest of the industry. CRL outperforms 57.89% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 6.60%, CRL is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for CRL is significantly below the industry average of 11.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROIC | 6.6% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
1.3 Margins
- Looking at the Operating Margin, with a value of 12.51%, CRL is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
- CRL's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 34.98%, CRL is doing worse than 63.16% of the companies in the same industry.
- In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% |
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
2. CRL Health Analysis
2.1 Basic Checks
- CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, CRL has less shares outstanding
- The number of shares outstanding for CRL has been reduced compared to 5 years ago.
- Compared to 1 year ago, CRL has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.26 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
- With a Altman-Z score value of 2.26, CRL perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
- CRL has a debt to FCF ratio of 4.13. This is a neutral value as CRL would need 4.13 years to pay back of all of its debts.
- The Debt to FCF ratio of CRL (4.13) is better than 73.68% of its industry peers.
- CRL has a Debt/Equity ratio of 0.68. This is a neutral value indicating CRL is somewhat dependend on debt financing.
- CRL's Debt to Equity ratio of 0.68 is on the low side compared to the rest of the industry. CRL is outperformed by 71.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Altman-Z | 2.26 |
ROIC/WACC0.63
WACC10.55%
2.3 Liquidity
- CRL has a Current Ratio of 1.29. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
- CRL's Current ratio of 1.29 is on the low side compared to the rest of the industry. CRL is outperformed by 80.70% of its industry peers.
- A Quick Ratio of 1.02 indicates that CRL should not have too much problems paying its short term obligations.
- CRL has a worse Quick ratio (1.02) than 80.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 |
3. CRL Growth Analysis
3.1 Past
- The earnings per share for CRL have decreased by -0.39% in the last year.
- CRL shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.78% yearly.
- The Revenue has decreased by -0.85% in the past year.
- CRL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.55% yearly.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
3.2 Future
- CRL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.31% yearly.
- CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.54% yearly.
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue Next Year1.31%
Revenue Next 2Y2.13%
Revenue Next 3Y2.87%
Revenue Next 5Y3.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. CRL Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 15.12 indicates a correct valuation of CRL.
- CRL's Price/Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 92.98% of the companies in the same industry.
- CRL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.70.
- CRL is valuated correctly with a Price/Forward Earnings ratio of 13.94.
- CRL's Price/Forward Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 89.47% of the companies in the same industry.
- CRL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.12 | ||
| Fwd PE | 13.94 |
4.2 Price Multiples
- CRL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CRL is cheaper than 94.74% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, CRL is valued cheaper than 87.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.76 | ||
| EV/EBITDA | 10.43 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.79
PEG (5Y)3.16
EPS Next 2Y8.74%
EPS Next 3Y8.89%
5. CRL Dividend Analysis
5.1 Amount
- CRL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CRL Fundamentals: All Metrics, Ratios and Statistics
155.46
+2.8 (+1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18 2026-02-18/bmo
Earnings (Next)05-05 2026-05-05/bmo
Inst Owners110.03%
Inst Owner Change3.95%
Ins Owners0.94%
Ins Owner Change5.84%
Market Cap7.65B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.28 (32.69%)
Short Float %6.07%
Short Ratio3.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)-6.85%
PT rev (3m)6.76%
EPS NQ rev (1m)-24.41%
EPS NQ rev (3m)-24.74%
EPS NY rev (1m)1.49%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-1.59%
Revenue NQ rev (3m)-1.68%
Revenue NY rev (1m)-0.39%
Revenue NY rev (3m)-0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.12 | ||
| Fwd PE | 13.94 | ||
| P/S | 1.91 | ||
| P/FCF | 14.76 | ||
| P/OCF | 10.38 | ||
| P/B | 2.42 | ||
| P/tB | 126.75 | ||
| EV/EBITDA | 10.43 |
EPS(TTM)10.28
EY6.61%
EPS(NY)11.15
Fwd EY7.17%
FCF(TTM)10.53
FCFY6.77%
OCF(TTM)14.98
OCFY9.64%
SpS81.56
BVpS64.28
TBVpS1.23
PEG (NY)1.79
PEG (5Y)3.16
Graham Number121.94
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.02% | ||
| ROE | -4.56% | ||
| ROCE | 8.35% | ||
| ROIC | 6.6% | ||
| ROICexc | 6.84% | ||
| ROICexgc | 14.71% | ||
| OM | 12.51% | ||
| PM (TTM) | N/A | ||
| GM | 34.98% | ||
| FCFM | 12.91% |
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | 4.13 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 54.34% | ||
| Cap/Sales | 5.46% | ||
| Interest Coverage | 4.94 | ||
| Cash Conversion | 81.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | 2.26 |
F-Score5
WACC10.55%
ROIC/WACC0.63
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y8.47%
EPS Next 2Y8.74%
EPS Next 3Y8.89%
EPS Next 5Y9.31%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year1.31%
Revenue Next 2Y2.13%
Revenue Next 3Y2.87%
Revenue Next 5Y3.54%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year25.47%
EBIT Next 3Y11.29%
EBIT Next 5Y9.93%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%
CHARLES RIVER LABORATORIES / CRL Fundamental Analysis FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for CRL stock?
The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 8.47% in the next year.